As a pharmaceutical company, identifying your qualifying R&D activities and associated expenditure is easy isn't it? But is it just the people in white coats in the R&D building or are there in fact more activities carried on in the organisation that you  haven't  considered? If so, what might these be, how much could they be worth and how do you most efficiently identify them? Doubtless you will already have made R&D tax credit claims, but wouldn't you like to be certain that you couldn't have claimed significantly more? Deloitte has an experienced and award-winning team of R&D specialists who have helped pharmaceutical clients to claim more R&D tax relief than was at first sight available.

In our experience
Pharmaceutical companies do not always claim all their activities that qualify under the R&D tax credits regime, often excluding areas of the business outside the clinical development laboratories.

Are you confident that all the activities associated with clinical testing have been fully claimed? We often see claims that do  not include clinical trials beyond phase III. Our experience in this area tells us that very often post regulatory approval studies will qualify. This is a significant area of expenditure, but making the optimum claim needs experience and deep technical knowledge.

All too often the claim centres purely on drug discovery and clinical testing but the relief is also available for aspects of process improvement which occur in the manufacturing operations.

For more information download our brochure about R&D tax relief opportunities for pharmaceutical companies (59KB, PDF).